DOCSLIB.ORG

The Expression and Role of LRRC31 in the Esophageal Epithelium

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Role of LRRC31 & LRRC32 in Allergic Inflammation A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Ph.D.) In the Immunology Graduate Program of the College of Medicine 2015 by Rahul Joseph D’Mello B.S., The Johns Hopkins University, 2009 Advisory Committee: Marc E. Rothenberg, M.D., Ph.D. (Chair) H. Leighton Grimes, Ph.D. Andrew B. Herr, Ph.D. Simon P. Hogan, Ph.D. Ian P. Lewkowich, Ph.D. Louis J. Muglia, M.D., Ph.D. ABSTRACT Eosinophilic esophagitis (EoE) is an allergic inflammatory disease of the esophagus that is caused by both genetic and environmental factors. Herein, we investigated leucine-rich repeat– containing protein 31 (LRRC31), a protein that regulates esophageal epithelial function, and LRRC32, which was genetically associated with EoE and allergic diseases. We show that LRRC31 increased in the esophagus of patients with active EoE. LRRC31 mRNA and protein were increased in differentiated, IL-13–treated esophageal epithelial (EPC2) cells grown at the air liquid interface (ALI). LRRC31 overexpressing EPC2 cells had increased epithelial barrier function and RNA sequencing analysis identified 38 dysregulated genes, including 5 kallikrein (KLK) proteases. Indeed, KLK protein and proteolytic activity levels were decreased in LRRC31- overexpressing EPC2 cells. KLK expression was similarly dysregulated in the esophagus of EoE patients and in IL-13–treated esophageal epithelial cells. Thus, we propose that LRRC31 is induced by IL-13 and modulates epithelial barrier function, potentially by regulating KLK expression. LRRC32 is an immune-related protein that is similar in structure to LRRC31. We identified rs2155219, a single nucleotide polymorphism (SNP) associated with EoE that was an enhancer of gene transcription. The minor allele at rs2155219 decreased the risk of developing EoE and increased esophageal expression of LRRC32 mRNA in EoE patients. In addition, IL-13 induced LRRC32 mRNA expression in EPC2 cells. We propose that LRRC32 is important for disease pathogenesis and decreased esophageal expression may correlate with lower risk of EoE. In conclusion, LRRC31 and LRRC32 are both involved in two independent pathways contributing to EoE pathogenesis. A further understanding of their roles in EoE and allergic diseases may facilitate the development of alternative therapeutics to improve the quality of life for patients. ! ii! ! iii! ACKNOWLEDGEMENTS I want to thank God, my parents Gilroy and Cheryl, my sister Esther, Dusty, and all my family and friends, especially my roommate Carlton, for getting me to this point in my life. I am grateful for my mentor Dr. Marc Rothenberg, Mel Mingler, Dr. Julie Caldwell, Dr. Ben Davis, Dr. Mark Rochman, Jared Travers, Kiran KC, Dr. Nurit Azouz, Dr. Ting Wen, Dr. Joe Sherrill, Dr. Tom Lu, and everyone in the Allergy & Immunology family who invested time, energy, and resources in my training and development as a scientist and a co-worker. I am grateful to the Medical Scientist Training Program and the Immunology Graduate Program, who helped guide and support me through medical and graduate school. I want to thank the mentors on my dissertation committee, Dr. Simon Hogan, Dr. Lee Grimes, Dr. Ian Lewkowich, Dr. Andy Herr, and Dr. Louis Muglia for their support, and Dr. Jim Heubi, who continues to guide me towards success. There were many times where I struggled but your patience and belief in me inspired me to persevere forward towards completion of my PhD. I want to thank my other mentors from all levels of my training, starting from high school with Mr. Bob Berg my biology teacher, to the Cleveland Clinic with Dr. Anthony Calabro, Dr. Aniq Darr, Dr. Ediuska Laurens, and Stephon Weber, at Hopkins with Dr. Sharon Gerecht and Dr. Guoming Sun, and here at University of Cincinnati and Cincinnati Children’s. I want to thank all the patients with EoE who participate in our studies – thank you for participating and sharing your tissue with us. I also want to thank all the administrative staff, especially Terry Fettig, Dr. Rothenberg’s administrative assistant, who helped coordinate meeting times and scheduling, and everyone I know who wished me the best on this endeavor. I would like to dedicate this dissertation to the memory of my grandparents Frank, Ettie, Selina, and Reginald. Thank you and God bless all of you. ! iv! TABLE OF CONTENTS ABSTRACT…………………………………..……………………………………………………………ii ACKNOWLEDGEMENTS…………………………..…………………………………………………...iii TABLE OF CONTENTS…………………………………..…………...………………………………..iv LIST OF FIGURES……………………………..……………………………………………………..…ix LIST OF TABLES……………………………..……………………………………………...………….xi LIST OF ABBREVIATIONS……………………..…………………………………………...…….…..xii PUBLICATIONS AND CONFERENCE PROCEEDINGS ARISING FROM THIS WORK………xiii STATEMENT OF AUTHORSHIP…………………………..………………………………….……..xiv CHAPTER 1: INTRODUCTION………………………………….……..……………………………….1 1.1. Allergic Diseases………………………………………………………..……………………….1 1.1.1. Introduction……………………………………….…….…..…..……………….1 1.1.2. Epidemiology of Allergic Diseases…..………...………...…..……………….1 1.1.3. General Pathogenesis of Allergic Diseases…………...…..……….……….2 1.1.4. Summary………………………………………………..…..….……...…….….3 1.2. Eosinophilic Esophagitis (EoE)..………………………………………...….……………….…4 1.2.1. Introduction……………………………………………..…………………….…4 1.2.2. History of EoE………...……………………...…………………………………4 1.2.3. Pathogenesis of EoE……………………………………………..……………5 1.2.4. EoE Therapy……………………………...………………...…………………12 1.2.5. Summary………………………………………………………….……………15 1.3. Epithelial Cells……..……………………………………………………………………………17 1.3.1. Introduction…………………………………………………………….………17 1.3.2. Epithelial Development...…………………...……………..…………………17 1.3.3. Epithelial Differentiation…………………………..……………….........……18 ! v! 1.3.4. Epithelial Barrier Function…………………………………………………....19 1.3.5. Epithelial Immunity……………………………………………..……………..19 1.3.6. Summary……………………………..……………………..…………………21 1.4. Interleuking-13 (IL-13)………….………………………………..……………………….……23 1.4.1. Introduction…………..……………………………………..………….………23 1.4.2. IL-13 Cytokine and IL-13 Receptor Structure…………….………......……23 1.4.3. Regulation of IL-13……………………………………………………………24 1.4.4. IL-13 Function…………………………………………………………………25 1.4.5. IL-13 in EoE………………………………………………………………..….26 1.4.6. Summary………………………………………..…………..…………………27 1.5. Kallikreins (KLKs)………………………………….………….……………..…………………28 1.5.1. Introduction……………………………………………….....…………………28 1.5.2. Serine Proteases……………………….…………………..…………………28 1.5.3. KLKs………………………………….……….……………..…………………29 1.5.4. Regulation of KLKs………………………………………..…………….……29 1.5.5. Epithelial KLKs….………………………………………..………...…………30 1.5.6. Summary………………………………………..…………..…………………31 1.6. Leucine-Rich Repeat (LRR) Domains……………………………………..…………………32 1.6.1. Introduction……………..…………………………………..……...…….……32 1.6.2. LRR Structure……………...……..………………………..………….………32 1.6.3. LRR Function……………………………...………………..…………………32 1.6.4. Summary………………………………………………..…………..…………33 1.7. Leucine-Rich Repeat–Containing Protein 32…………………..…………………….……..35 1.7.1. Introduction……………………………………..…………..….………………35 1.7.2. LRRC32 Structure………...…………………………..………………………35 1.7.3. LRRC32 Function…………………………………………..…………………36 ! vi! 1.7.4. Summary…………………………..………………………..…………………37 1.8. References…...……………………………………………..………………..…………………38 CHAPTER 2: LRRC31 IS INDUCED BY IL-13 AND REGULATES KALLIKREIN EXPERSSION AND BARRIER FUNCTION IN THE ESOPHAGEAL EPITHELIUM…………………………...,…68 2.1. Abstract…...……………………………………………………………………………………..69 2.2. Introduction……..……………………………………………………………………………….70 2.3. Results….…………………………………………………………………………………….…72 2.3.1. Identification of LRRC31….……………………………………………….…72 2.3.2. LRRC31 is specifically induced in EoE……………………….………….…72 2.3.3. LRRC31 is expressed in the colon and mucosal tissue………….…….…72 2.3.4. LRRC31 mRNA parallels disease activity……………………………….…73 2.3.5. LRRC31 mRNA correlates with esophageal eosinophilia and IL13 mRNA…………………………………………………………………………..73 2.3.6. IL-13 induces LRRC31 in epithelial cells….…………………….……….…74 2.3.7. Overexpression of LRRC31 increases barrier function……………..…….76 2.3.8. LRRC31 regulates epithelial serine proteases….…………………...….…77 2.3.9. Loss of LRRC31 increases KLK expression….………………...……….…78 2.3.10. KLK expression in EoE and in response to IL-13….………..…………….79 2.4. Discussion….……………………………………………………………………...……………80 2.5. Methods…………………………………………………………………….……...……………84 2.6. Acknowledgements……..……………………………………………….……...……..………88 2.7. References…...…………………………………………………………….……...……………89 2.8. Figures…………………………………………………………………….……...……….…….95 ! vii! CHAPTER 3: ESOPHAGEAL LRRC32 EXPRESSION IS REGULATED BY ALLELIC VARIATION AT rs2155219……………………………………..……………………...……….……112 3.1. Abstract…..……………………………………………………………….……...……………113 3.2. Introduction……..…………………………………………..……………….……...…………114 3.3. Results……………………….……………………………………….……...………………...117 3.3.1. EoE shares genetic associations with other allergic diseases……….…117 3.3.2. Chromosome 11q13 has SNPs associated with allergic diseases…….117 3.3.3. Epigenetic and transcriptional landscape at rs2155219……...…………118 3.3.4. Expression of LRRC32, C11ORF30, and CAPN5 in the esophagus ....119 3.3.5. Expression of LRRC32, C11ORF30, and CAPN5 in epithelial cells.…..120 3.4. Discussion….…………………………………………………………...…...………………..122 3.5. Methods…………………………………...………………………….……...………………..127 3.6. Acknowledgments…..……...……………………….……………….……...………………..131 3.7. References…..……………………………………………………….……...………………..132 3.8. Figures....…………………………………………………………….……...…………………139 CHAPTER 4: GENERAL DISCUSSION
Recommended publications
  • A Missense Polymorphism in the Putative Pheromone Receptor Gene VN1R1 Is Associated with Sociosexual Behavior

    A Missense Polymorphism in the Putative Pheromone Receptor Gene VN1R1 Is Associated with Sociosexual Behavior

    OPEN Citation: Transl Psychiatry (2017) 7, e1102; doi:10.1038/tp.2017.70 www.nature.com/tp ORIGINAL ARTICLE A missense polymorphism in the putative pheromone receptor gene VN1R1 is associated with sociosexual behavior S Henningsson1, D Hovey1, K Vass1, H Walum2,3,4,5, K Sandnabba6, P Santtila6, P Jern6 and L Westberg1 Pheromones regulate social and reproductive behavior in most mammalian species. These effects are mediated by the vomeronasal and main olfactory systems. Effects of putative pheromones on human neuroendocrine activity, brain activity and attractiveness ratings suggest that humans may communicate via similar chemosignaling. Here we studied two samples of younger and older individuals, respectively, with respect to one nonsynonymous polymorphism in the gene encoding the human vomeronasal type-1 receptor 1, VN1R1, and one nonsynonymous polymorphism in the gene encoding the olfactory receptor OR7D4. Participants in both samples had self-reported their sociosexual behavior using the sociosexual orientation inventory, including questions regarding lifetime number of one-night stands, number of partners last year and expected number of partners the coming 5 years. In women, there was a significant association between the VN1R1 polymorphism and sociosexual behavior in both samples, driven specifically by the question regarding one-night stands. Our results support the hypothesis that human social interaction is modulated by communication via chemosignaling. Translational Psychiatry (2017) 7, e1102; doi:10.1038/tp.2017.70; published
  • Supplementary Information Changes in the Plasma Proteome At

    Supplementary Information Changes in the Plasma Proteome At

    Supplementary Information Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease Julia Muenchhoff1, Anne Poljak1,2,3, Anbupalam Thalamuthu1, Veer B. Gupta4,5, Pratishtha Chatterjee4,5,6, Mark Raftery2, Colin L. Masters7, John C. Morris8,9,10, Randall J. Bateman8,9, Anne M. Fagan8,9, Ralph N. Martins4,5,6, Perminder S. Sachdev1,11,* Supplementary Figure S1. Ratios of proteins differentially abundant in asymptomatic carriers of PSEN1 and APP Dutch mutations. Mean ratios and standard deviations of plasma proteins from asymptomatic PSEN1 mutation carriers (PSEN1) and APP Dutch mutation carriers (APP) relative to reference masterpool as quantified by iTRAQ. Ratios that significantly differed are marked with asterisks (* p < 0.05; ** p < 0.01). C4A, complement C4-A; AZGP1, zinc-α-2-glycoprotein; HPX, hemopexin; PGLYPR2, N-acetylmuramoyl-L-alanine amidase isoform 2; α2AP, α-2-antiplasmin; APOL1, apolipoprotein L1; C1 inhibitor, plasma protease C1 inhibitor; ITIH2, inter-α-trypsin inhibitor heavy chain H2. 2 A) ADAD)CSF) ADAD)plasma) B) ADAD)CSF) ADAD)plasma) (Ringman)et)al)2015)) (current)study)) (Ringman)et)al)2015)) (current)study)) ATRN↓,%%AHSG↑% 32028% 49% %%%%%%%%HC2↑,%%ApoM↓% 24367% 31% 10083%% %%%%TBG↑,%%LUM↑% 24256% ApoC1↓↑% 16565% %%AMBP↑% 11738%%% SERPINA3↓↑% 24373% C6↓↑% ITIH2% 10574%% %%%%%%%CPN2↓%% ↓↑% %%%%%TTR↑% 11977% 10970% %SERPINF2↓↑% CFH↓% C5↑% CP↓↑% 16566% 11412%% 10127%% %%ITIH4↓↑% SerpinG1↓% 11967% %%ORM1↓↑% SerpinC1↓% 10612% %%%A1BG↑%%% %%%%FN1↓% 11461% %%%%ITIH1↑% C3↓↑% 11027% 19325% 10395%% %%%%%%HPR↓↑% HRG↓% %%% 13814%% 10338%% %%% %ApoA1 % %%%%%%%%%GSN↑% ↓↑ %%%%%%%%%%%%ApoD↓% 11385% C4BPA↓↑% 18976%% %%%%%%%%%%%%%%%%%ApoJ↓↑% 23266%%%% %%%%%%%%%%%%%%%%%%%%%%ApoA2↓↑% %%%%%%%%%%%%%%%%%%%%%%%%%%%%A2M↓↑% IGHM↑,%%GC↓↑,%%ApoB↓↑% 13769% % FGA↓↑,%%FGB↓↑,%%FGG↓↑% AFM↓↑,%%CFB↓↑,%% 19143%% ApoH↓↑,%%C4BPA↓↑% ApoA4↓↑%%% LOAD/MCI)plasma) LOAD/MCI)plasma) LOAD/MCI)plasma) LOAD/MCI)plasma) (Song)et)al)2014)) (Muenchhoff)et)al)2015)) (Song)et)al)2014)) (Muenchhoff)et)al)2015)) Supplementary Figure S2.
  • Mouse Fscn3 Conditional Knockout Project (CRISPR/Cas9)

    Mouse Fscn3 Conditional Knockout Project (CRISPR/Cas9)

    https://www.alphaknockout.com Mouse Fscn3 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Fscn3 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Fscn3 gene (NCBI Reference Sequence: NM_019569 ; Ensembl: ENSMUSG00000029707 ) is located on Mouse chromosome 6. 7 exons are identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 6 (Transcript: ENSMUST00000031719). Exon 2 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Fscn3 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-176I9 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 2 starts from about 9.71% of the coding region. The knockout of Exon 2 will result in frameshift of the gene. The size of intron 1 for 5'-loxP site insertion: 1817 bp, and the size of intron 2 for 3'-loxP site insertion: 839 bp. The size of effective cKO region: ~1197 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 7 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Homology arm Exon of mouse Fscn3 cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats.
  • Ovarian Gene Expression in the Absence of FIGLA, an Oocyte

    Ovarian Gene Expression in the Absence of FIGLA, an Oocyte

    BMC Developmental Biology BioMed Central Research article Open Access Ovarian gene expression in the absence of FIGLA, an oocyte-specific transcription factor Saurabh Joshi*1, Holly Davies1, Lauren Porter Sims2, Shawn E Levy2 and Jurrien Dean1 Address: 1Laboratory of Cellular and Developmental Biology, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA and 2Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA Email: Saurabh Joshi* - [email protected]; Holly Davies - [email protected]; Lauren Porter Sims - [email protected]; Shawn E Levy - [email protected]; Jurrien Dean - [email protected] * Corresponding author Published: 13 June 2007 Received: 11 December 2006 Accepted: 13 June 2007 BMC Developmental Biology 2007, 7:67 doi:10.1186/1471-213X-7-67 This article is available from: http://www.biomedcentral.com/1471-213X/7/67 © 2007 Joshi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Ovarian folliculogenesis in mammals is a complex process involving interactions between germ and somatic cells. Carefully orchestrated expression of transcription factors, cell adhesion molecules and growth factors are required for success. We have identified a germ-cell specific, basic helix-loop-helix transcription factor, FIGLA (Factor In the GermLine, Alpha) and demonstrated its involvement in two independent developmental processes: formation of the primordial follicle and coordinate expression of zona pellucida genes. Results: Taking advantage of Figla null mouse lines, we have used a combined approach of microarray and Serial Analysis of Gene Expression (SAGE) to identify potential downstream target genes.
  • Mammalian Male Germ Cells Are Fertile Ground for Expression Profiling Of

    Mammalian Male Germ Cells Are Fertile Ground for Expression Profiling Of

    REPRODUCTIONREVIEW Mammalian male germ cells are fertile ground for expression profiling of sexual reproduction Gunnar Wrobel and Michael Primig Biozentrum and Swiss Institute of Bioinformatics, Klingelbergstrasse 50-70, 4056 Basel, Switzerland Correspondence should be addressed to Michael Primig; Email: [email protected] Abstract Recent large-scale transcriptional profiling experiments of mammalian spermatogenesis using rodent model systems and different types of microarrays have yielded insight into the expression program of male germ cells. These studies revealed that an astonishingly large number of loci are differentially expressed during spermatogenesis. Among them are several hundred transcripts that appear to be specific for meiotic and post-meiotic germ cells. This group includes many genes that were pre- viously implicated in spermatogenesis and/or fertility and others that are as yet poorly characterized. Profiling experiments thus reveal candidates for regulation of spermatogenesis and fertility as well as targets for innovative contraceptives that act on gene products absent in somatic tissues. In this review, consolidated high density oligonucleotide microarray data from rodent total testis and purified germ cell samples are analyzed and their impact on our understanding of the transcriptional program governing male germ cell differentiation is discussed. Reproduction (2005) 129 1–7 Introduction 2002, Sadate-Ngatchou et al. 2003) and the absence of cAMP responsive-element modulator (Crem) and deleted During mammalian male
  • Download Download

    Download Download

    Supplementary Figure S1. Results of flow cytometry analysis, performed to estimate CD34 positivity, after immunomagnetic separation in two different experiments. As monoclonal antibody for labeling the sample, the fluorescein isothiocyanate (FITC)- conjugated mouse anti-human CD34 MoAb (Mylteni) was used. Briefly, cell samples were incubated in the presence of the indicated MoAbs, at the proper dilution, in PBS containing 5% FCS and 1% Fc receptor (FcR) blocking reagent (Miltenyi) for 30 min at 4 C. Cells were then washed twice, resuspended with PBS and analyzed by a Coulter Epics XL (Coulter Electronics Inc., Hialeah, FL, USA) flow cytometer. only use Non-commercial 1 Supplementary Table S1. Complete list of the datasets used in this study and their sources. GEO Total samples Geo selected GEO accession of used Platform Reference series in series samples samples GSM142565 GSM142566 GSM142567 GSM142568 GSE6146 HG-U133A 14 8 - GSM142569 GSM142571 GSM142572 GSM142574 GSM51391 GSM51392 GSE2666 HG-U133A 36 4 1 GSM51393 GSM51394 only GSM321583 GSE12803 HG-U133A 20 3 GSM321584 2 GSM321585 use Promyelocytes_1 Promyelocytes_2 Promyelocytes_3 Promyelocytes_4 HG-U133A 8 8 3 GSE64282 Promyelocytes_5 Promyelocytes_6 Promyelocytes_7 Promyelocytes_8 Non-commercial 2 Supplementary Table S2. Chromosomal regions up-regulated in CD34+ samples as identified by the LAP procedure with the two-class statistics coded in the PREDA R package and an FDR threshold of 0.5. Functional enrichment analysis has been performed using DAVID (http://david.abcc.ncifcrf.gov/)
  • Mechanism of Interleukin-1- and Tumor Necrosis Factor Α-Dependent Regulation of the Α1-Antichymotrypsin Gene in Human Astrocyt

    Mechanism of Interleukin-1- and Tumor Necrosis Factor Α-Dependent Regulation of the Α1-Antichymotrypsin Gene in Human Astrocyt

    The Journal of Neuroscience, October 15, 2000, 20(20):7510–7516 Mechanism of Interleukin-1- and Tumor Necrosis Factor ␣- ␣ Dependent Regulation of the 1-Antichymotrypsin Gene in Human Astrocytes Tomasz Kordula,1 Marcin Bugno,1 Russell E. Rydel,2 and James Travis3 1Institute of Molecular Biology, Jagiellonian University, 31-120 Krako´ w, Poland, 2Elan Pharmaceuticals, South San Francisco, California 94080, and 3Department of Biochemistry and Molecular Biology, The University of Georgia, Athens, Georgia 30602 ␣ The expression of 1-antichymotrypsin (ACT) is significantly en- which bind nuclear factor kB (NF-kB) and one that binds activat- hanced in affected brain regions in Alzheimer’s disease. This ing protein 1 (AP-1). All of these elements contribute to the full serine proteinase inhibitor specifically colocalizes with filamen- responsiveness of the ACT gene to both cytokines, as deter- tous ␤-amyloid deposits and recently has been shown to influ- mined by deletion and mutational analysis. The 5Ј NF-kB high- ence both formation and destabilization of ␤-amyloid fibrils. In affinity binding site and AP-1 element contribute most to the the brain, ACT is expressed in astrocytes, and interleukin-1 (IL-1), enhancement of gene transcription in response to TNF and IL-1. tumor necrosis factor ␣ (TNF), oncostatin M (OSM), and IL-6/ In addition, we demonstrate that the 5Ј untranslated region of the soluble IL-6 receptor complexes control synthesis of this inhibi- ACT mRNA does not contribute to cytokine-mediated activation. tor. Here, we characterize a molecular mechanism responsible Finally, we find that overexpression of the NF-kB inhibitor (IkB) for both IL-1 and TNF-induced expression of ACT gene in astro- totally inhibits any activation mediated by the newly identified cytes.
  • Genetics of Aggressive Behavior: an Overview Kim Veroude,1 Yanli Zhang-James,2,3 No�Elia Fern�Andez-Castillo,4,5,6 Mireille J

    Genetics of Aggressive Behavior: an Overview Kim Veroude,1 Yanli Zhang-James,2,3 NoElia FernAndez-Castillo,4,5,6 Mireille J

    RESEARCH ARTICLE Neuropsychiatric Genetics Genetics of Aggressive Behavior: An Overview Kim Veroude,1 Yanli Zhang-James,2,3 Noelia Fernandez-Castillo,4,5,6 Mireille J. Bakker,1 Bru Cormand,4,5,6 and Stephen V. Faraone2,3,7* 1Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboudumc, Nijmegen, The Netherlands 2Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York 3Departments of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York 4Departament de Genetica, Facultat de Biologia, Universitat de Barcelona, Catalonia, Spain 5Institut de Biomedicina de la Universitat de Barcelona (IBUB), Catalonia, Spain 6Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Spain 7K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen, Bergen, Norway Manuscript Received: 22 April 2015; Manuscript Accepted: 5 August 2015 The Research Domain Criteria (RDoC) address three types of aggression: frustrative non-reward, defensive aggression and How to Cite this Article: offensive/proactive aggression. This review sought to present Veroude K, Zhang-James Y, Fernandez- the evidence for genetic underpinnings of aggression and to Castillo N, Bakker MJ, Cormand B, determine to what degree prior studies have examined pheno- Faraone SV. 2016. Genetics of Aggressive types that fit into the RDoC framework. Although the constructs Behavior: An Overview. of defensive and offensive aggression have been widely used in the animal genetics literature, the human literature is mostly Am J Med Genet Part B 171B:3–43. agnostic with regard to all the RDoC constructs. We know from twin studies that about half the variance in behavior may be explained by genetic risk factors.
  • A Web-Platform for Analysis of Host Factors Involved in Viral Infections Discovered by Genome Wide Rnai Screen

    A Web-Platform for Analysis of Host Factors Involved in Viral Infections Discovered by Genome Wide Rnai Screen

    Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is © The Royal Society of Chemistry 2017 vhfRNAi: A web-platform for analysis of host factors involved in viral infections discovered by genome wide RNAi screen Anamika Thakur#, Abid Qureshi# and Manoj Kumar* Bioinformatics Centre, Institute of Microbial Technology, Council of Scientific and Industrial Research, Sector 39A, Chandigarh-160036, India #Equal contribution * To whom correspondence should be addressed. Tel, 91-172-6665453; Fax, 91-172- 2690585; 91-172-2690632; Email, [email protected] Supplementary Tables Table S1: Statistics of unique and duplicate host factors in each virus Table S2: Table denoting genes common among different viruses Table S3: Statistics of GWAS analysis Table S1. Statistics of unique and duplicate host factors in each virus S. No. Virus Unique-Entries Duplicate-Entries 1. Adeno-associated virus (AAV) 926 533 2. Avian influenza virus (AIV) 0 11 3. Borna disease virus (BDV) 14 20 4. Dengue virus 2 (DEN-2) 27 13 5. Hepatitis C virus (HCV) 236 213 6. Human immunodeficiency virus 1 (HIV) 1388 857 7. Human parainfluenza virus 3 (HPIV-3) 0 27 8. Human herpesvirus 1 (HSV-1) 34 38 9. Influenza A virus (IAV) 700 513 10. Lymphocytic choriomeningitis virus (LCMV) 0 54 11. Marburgvirus (MARV) 0 11 12. Poliovirus (PV) 3340 1035 13. Rotavirus (RV) 347 175 14. Sendai virus (SeV) 32 27 15. Sindbis virus (SIV) 70 41 16. Vaccinia virus (VACV) 482 296 17. Vesicular stomatitis virus (VSV) 9 78 18. West Nile virus (WNV) 313 137 Table S1. Statistics of unique host factors for each virus having overlapping and unique factors in different viruses Non-overlap – Overall- S.
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • Genetics of Aggressive Behavior: an Overview

    Genetics of Aggressive Behavior: an Overview

    The influence of genes on “positive valence systems” constructs: A systematic review Item Type Article Authors Hess, Jonathan L.; Kawaguchi, Daniel M.; Wagner, Kayla E.; Faraone, Stephen V.; Glatt, Stephen J. Citation Hess, JL, Kawaguchi, DM, Wagner, KE, Faraone, SV, Glatt, SJ. 2015. The Influence of Genes on “Positive Valence Systems” Constructs: A Systematic Review. Am J Med Genet Part B 171B: 92– 110. DOI 10.1002/ajmg.b.32382 Publisher Wiley Rights Attribution-NonCommercial-NoDerivatives 4.0 International Download date 26/09/2021 01:12:21 Item License http://doi.wiley.com/10.1002/tdm_license_1.1 Link to Item http://hdl.handle.net/20.500.12648/1795 See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/281608624 Genetics of Aggressive Behavior: An Overview Article in American Journal of Medical Genetics Part B Neuropsychiatric Genetics · September 2015 DOI: 10.1002/ajmg.b.32364 CITATIONS READS 81 1,596 6 authors, including: Yanli Zhang-James Noèlia Fernàndez-Castillo State University of New York Upstate Medical University University of Barcelona 65 PUBLICATIONS 1,992 CITATIONS 102 PUBLICATIONS 848 CITATIONS SEE PROFILE SEE PROFILE Mireille J. Bakker Bru Cormand Radboud University Medical Centre (Radboudumc) University of Barcelona 8 PUBLICATIONS 272 CITATIONS 311 PUBLICATIONS 10,197 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: Aggression Genetics View project Trastorno por deficit de atencion con hiperactividad en la clinica pediatrica View project All content following this page was uploaded by Noèlia Fernàndez-Castillo on 25 November 2017. The user has requested enhancement of the downloaded file.
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease

    Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease

    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................